Literature DB >> 25725585

Apoptosis and anergy of T cell induced by pancreatic stellate cells-derived galectin-1 in pancreatic cancer.

Dong Tang1, Jun Gao, Sen Wang, Zhongxu Yuan, Nianyuan Ye, Yang Chong, Chuanqi Xu, Xuetong Jiang, Bin Li, Wei Yin, Yi Miao, Daorong Wang, Kuirong Jiang.   

Abstract

Galectin-1, a β-galactoside-binding protein implicated in cancer cell immune privilege, was highly expressed in activated pancreatic stellate cells (PSCs). This study was designed to investigate the relationship between PSC-derived galectin-1 and tumor immunity in pancreatic cancer. Isolated PSCs were identified as normal pancreas cells (hNPSCs) or pancreatic cancer cells (hCaPSCs) by immunohistochemical staining for α-SMA and vimentin, and galectin-1 expression was evaluated by Western blotting and quantitative RT-PCR. Apoptosis, caspase activity, and cytokine production (IL-6, IL-10, TNF-β, and IFN-γ) of T cells co-cultured with PSCs were evaluated, and immunohistochemical staining of galectin-1 was correlated with CD3 and clinicopathological variables in 66 pancreatic cancer and 10 normal pancreatic tissue samples. hCaPSCs exhibited higher galectin-1 expression than did hNPSCs, and hCaPSCs induced higher levels of apoptosis in T cells following co-culture. hCaPSCs activated caspase-9 and caspase-3 in the mitochondrial apoptotic pathway and stimulated secretion of Th2 cytokines (IL-6 and IL-10) but decreased secretion of Th1 cytokines (TNF-β and IFN-γ), compared with hNPSCs. Immunohistochemical staining indicated that galectin-1 and CD3 were more highly expressed in pancreatic cancer tissue. Galectin-1 expression was highest in poorly differentiated pancreatic cancer cells and lowest in well-differentiated pancreatic cancer cells and was associated with tumor size, lymph node metastasis, differentiation, and UICC stage. However, CD3 expression showed the opposite trend and was highest in well-differentiated pancreatic cancer cells and was associated with tumor differentiation and UICC stage. High expression of galectin-1 was associated with short survival, as was low expression of CD3. hCaPSC-derived galectin-1 enhanced apoptosis and anergy of T cells in pancreatic cancer, which contributes to the immune escape of pancreatic cancer cells.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25725585     DOI: 10.1007/s13277-015-3233-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  49 in total

Review 1.  Galectins as modulators of cell adhesion.

Authors:  R C Hughes
Journal:  Biochimie       Date:  2001-07       Impact factor: 4.079

2.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

3.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer.

Authors:  Peter J Campbell; Shinichi Yachida; Laura J Mudie; Philip J Stephens; Erin D Pleasance; Lucy A Stebbings; Laura A Morsberger; Calli Latimer; Stuart McLaren; Meng-Lay Lin; David J McBride; Ignacio Varela; Serena A Nik-Zainal; Catherine Leroy; Mingming Jia; Andrew Menzies; Adam P Butler; Jon W Teague; Constance A Griffin; John Burton; Harold Swerdlow; Michael A Quail; Michael R Stratton; Christine Iacobuzio-Donahue; P Andrew Futreal
Journal:  Nature       Date:  2010-10-28       Impact factor: 49.962

4.  Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation.

Authors:  H D Park; Y Lee; Y K Oh; J G Jung; Y W Park; K Myung; K-H Kim; S S Koh; D-S Lim
Journal:  Oncogene       Date:  2010-08-30       Impact factor: 9.867

5.  Anti-CD43 and anti-galectin-1 autoantibodies in patients with systemic lupus erythematosus.

Authors:  J L Montiel; A Monsiváis-Urenda; N Figueroa-Vega; J F Moctezuma; R Burgos-Vargas; R González-Amaro; Y Rosenstein
Journal:  Scand J Rheumatol       Date:  2010       Impact factor: 3.641

6.  Beta-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells.

Authors:  C Blaser; M Kaufmann; C Müller; C Zimmermann; V Wells; L Mallucci; H Pircher
Journal:  Eur J Immunol       Date:  1998-08       Impact factor: 5.532

7.  Pancreatic stellate cells: partners in crime with pancreatic cancer cells.

Authors:  Alain Vonlaufen; Swapna Joshi; Changfa Qu; Phoebe A Phillips; Zhihong Xu; Nicole R Parker; Cheryl S Toi; Romano C Pirola; Jeremy S Wilson; David Goldstein; Minoti V Apte
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

8.  Galectin-1 induces nuclear translocation of endonuclease G in caspase- and cytochrome c-independent T cell death.

Authors:  H P Hahn; M Pang; J He; J D Hernandez; R-Y Yang; L Y Li; X Wang; F-T Liu; L G Baum
Journal:  Cell Death Differ       Date:  2004-12       Impact factor: 15.828

Review 9.  Pancreatic cancer microenvironment.

Authors:  Jörg Kleeff; Philipp Beckhove; Irene Esposito; Stephan Herzig; Peter E Huber; J Matthias Löhr; Helmut Friess
Journal:  Int J Cancer       Date:  2007-08-15       Impact factor: 7.396

10.  Identification, culture, and characterization of pancreatic stellate cells in rats and humans.

Authors:  M G Bachem; E Schneider; H Gross; H Weidenbach; R M Schmid; A Menke; M Siech; H Beger; A Grünert; G Adler
Journal:  Gastroenterology       Date:  1998-08       Impact factor: 22.682

View more
  29 in total

1.  PRSS1 mutations and the proteinase/antiproteinase imbalance in the pathogenesis of pancreatic cancer.

Authors:  Qiang Yi; Feng Dong; Liqing Lin; Qicai Liu; Shu Chen; Feng Gao; Qingliang He
Journal:  Tumour Biol       Date:  2015-11-06

Review 2.  Engineering galectin-glycan interactions for immunotherapy and immunomodulation.

Authors:  Shaheen A Farhadi; Gregory A Hudalla
Journal:  Exp Biol Med (Maywood)       Date:  2016-05

Review 3.  Kras and Tumor Immunity: Friend or Foe?

Authors:  Jane Cullis; Shipra Das; Dafna Bar-Sagi
Journal:  Cold Spring Harb Perspect Med       Date:  2018-09-04       Impact factor: 6.915

4.  Down-expression of poly(ADP-ribose) polymerase in p53-regulated pancreatic cancer cells.

Authors:  Zhenyu Hou; Yunfeng Cui; Huizhi Xing; Xiaoyan Mu
Journal:  Oncol Lett       Date:  2017-11-29       Impact factor: 2.967

Review 5.  The emerging role of galectins in high-fatality cancers.

Authors:  Cherylane Dubé-Delarosbil; Yves St-Pierre
Journal:  Cell Mol Life Sci       Date:  2017-11-08       Impact factor: 9.261

6.  The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer.

Authors:  Hai Hu; Jun-Jie Hang; Ting Han; Meng Zhuo; Feng Jiao; Li-Wei Wang
Journal:  Tumour Biol       Date:  2016-01-06

7.  Galectin-1 mediates TGF-β-induced transformation from normal fibroblasts into carcinoma-associated fibroblasts and promotes tumor progression in gastric cancer.

Authors:  Lingyan Zheng; Cong Xu; Zhonghai Guan; Xingyun Su; Zhenzhen Xu; Jiang Cao; Lisong Teng
Journal:  Am J Transl Res       Date:  2016-04-15       Impact factor: 4.060

8.  Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk.

Authors:  Carlos A Orozco; Neus Martinez-Bosch; Pedro E Guerrero; Judith Vinaixa; Tomás Dalotto-Moreno; Mar Iglesias; Mireia Moreno; Magdolna Djurec; Françoise Poirier; Hans-Joachim Gabius; Martin E Fernandez-Zapico; Rosa F Hwang; Carmen Guerra; Gabriel A Rabinovich; Pilar Navarro
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-03       Impact factor: 11.205

Review 9.  Emerging trends in the immunotherapy of pancreatic cancer.

Authors:  Kasturi Banerjee; Sushil Kumar; Kathleen A Ross; Shailendra Gautam; Brittany Poelaert; Mohd Wasim Nasser; Abhijit Aithal; Rakesh Bhatia; Michael J Wannemuehler; Balaji Narasimhan; Joyce C Solheim; Surinder K Batra; Maneesh Jain
Journal:  Cancer Lett       Date:  2017-12-12       Impact factor: 8.679

10.  Deguelin Induces the Apoptosis of Lung Squamous Cell Carcinoma Cells through Regulating the Expression of Galectin-1.

Authors:  Bing Yan; Dejian Zhao; Yinan Yao; Zhang Bao; Guohua Lu; Jianying Zhou
Journal:  Int J Biol Sci       Date:  2016-05-25       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.